Peachell P T, Columbo M, Kagey-Sobotka A, Lichtenstein L M, Marone G
Department of Medicine, Johns Hopkins University School of Medicine, Good Samaritan Hospital, Baltimore, Maryland 21239.
Am Rev Respir Dis. 1988 Nov;138(5):1143-51. doi: 10.1164/ajrccm/138.5.1143.
Micromolar concentrations of adenosine were found to potentiate the release of histamine and leukotriene C4 (LTC4) from immunologically activated human lung mast cells (HLMC). Structurally modified congeners of adenosine including 5'-N-ethylcarboxamideadenosine (NECA) and R-phenylisopropyladenosine (R-PIA) also potentiated mediator release. A rank order of potency was established where NECA greater than R-PIA for the potentiation of both LTC4 production and histamine secretion. Mast cells isolated by either enzymatic or mechanical means from human lung parenchyma were both similarly responsive to the modulatory effects of adenosine and analogues, and the potency series of NECA greater than R-PIA also applied. Moreover, histamine release induced by the calcium ionophore A23187 was augmented by NECA, R-PIA, and adenosine and in that potency order. Dipyridamole, an agent thought to impede the intracellular uptake of adenosine, failed to reverse the nucleoside's enhancement of IgE-mediated secretion. The irreversible inhibitor of adenosine deaminase, deoxycoformycin, did not modify the adenosine enhancement of stimulated secretion. Low concentrations of methylxanthines, which antagonize responses mediated at cell surface adenosine receptors, were inconsistent in their effects. Theophylline modestly reversed the adenosine-induced potentiation of IgE-mediated LTC4 generation but not histamine release. Studies employing 8-phenyltheophylline were complicated by the methylxanthine possessing inhibitory properties of its own at concentrations expected to antagonize a nucleoside-mediated effect. In total, these results suggest that the response of HLMC to adenosine describes properties most consistent with an A2/Ra-like process, although an interaction via an, as yet, uncharacterized cell surface receptor cannot be excluded.
已发现微摩尔浓度的腺苷可增强免疫激活的人肺肥大细胞(HLMC)释放组胺和白三烯C4(LTC4)。腺苷的结构修饰类似物,包括5'-N-乙基甲酰胺腺苷(NECA)和R-苯异丙基腺苷(R-PIA),也能增强介质释放。建立了一个效能顺序,即NECA对LTC4产生和组胺分泌的增强作用大于R-PIA。通过酶法或机械法从人肺实质分离的肥大细胞对腺苷及其类似物的调节作用同样敏感,并且NECA大于R-PIA的效能顺序也适用。此外,钙离子载体A23187诱导的组胺释放被NECA、R-PIA和腺苷增强,且按该效能顺序增强。双嘧达莫,一种被认为会阻碍腺苷细胞内摄取的药物,未能逆转核苷对IgE介导分泌的增强作用。腺苷脱氨酶的不可逆抑制剂,脱氧助间型霉素,并未改变腺苷对刺激分泌的增强作用。低浓度的甲基黄嘌呤,可拮抗细胞表面腺苷受体介导的反应,其作用并不一致。茶碱适度逆转了腺苷诱导的IgE介导的LTC4生成增强,但未逆转组胺释放。使用8-苯基茶碱的研究因甲基黄嘌呤在预期拮抗核苷介导作用的浓度下自身具有抑制特性而变得复杂。总体而言,这些结果表明,HLMC对腺苷的反应描述的特性与A2/Ra样过程最为一致,尽管通过尚未明确的细胞表面受体的相互作用也不能排除。